Empath Ventures

Xylo Bio is a drug development company focused on next-generation psychedelic-inspired therapeutics for psychiatric and neurological disorders. Through a psychedelic therapeutic platform, it aims to develop non-hallucinogenic, rapid-acting medicines that can be widely available and provide improvements over current SSRI treatments. The company seeks to rewire neural circuits and restore brain function, enabling clinicians to optimize care and expand treatment options beyond traditional antidepressants.

Motif Neurotech specializes in developing minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses, focusing initially on treatment-resistant depression. The company aims to restore hope and improve quality of life by providing personalized treatments that repair neural circuits.

TARA Mind is a company dedicated to improving mental health outcomes by closing gaps in therapeutic accessibility and affordability for high-risk individuals. It offers employers a supplemental benefit that provides safe, affordable access to life-changing mental health therapies, focusing on treatment-resistant depression.

Nue Life is a company focused on enhancing mental wellness through scientifically validated treatments. It offers an innovative therapeutic ecosystem that includes at-home ketamine therapy, an interactive companion app, and virtual aftercare programs. The application utilizes knowledge graphs and artificial intelligence to provide personalized, evidence-based therapies, assisting users in diagnosing and addressing their mental health conditions. By combining advanced technology with therapeutic practices, Nue Life aims to improve brain function, performance, and overall longevity for its users.

Motif Neurotech specializes in developing minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses, focusing initially on treatment-resistant depression. The company aims to restore hope and improve quality of life by providing personalized treatments that repair neural circuits.

Xylo Bio is a drug development company focused on next-generation psychedelic-inspired therapeutics for psychiatric and neurological disorders. Through a psychedelic therapeutic platform, it aims to develop non-hallucinogenic, rapid-acting medicines that can be widely available and provide improvements over current SSRI treatments. The company seeks to rewire neural circuits and restore brain function, enabling clinicians to optimize care and expand treatment options beyond traditional antidepressants.